A Randomized Placebo Controlled Clinical Trial to Determine the Impact of Digestion Resistant Starch MSPrebiotic(®) on Glucose, Insulin, and Insulin Resistance in Elderly and Mid-Age Adults.
A Randomized Placebo Controlled Clinical Trial to Determine the Impact of Digestion Resistant Starch MSPrebiotic(®) on Glucose, Insulin, and Insulin Resistance in Elderly and Mid-Age Adults.
复制标题
一项随机安慰剂对照临床试验，以确定抗消化淀粉M +生育（®）对老年和中年龄成年人中葡萄糖，胰岛素和胰岛素抵抗的影响。
DOI：
10.3389/fmed.2017.00260
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Hiebert B
中科院分区：
文献类型：
--
作者：
Alfa MJ;Strang D;Tappia PS;Olson N;DeGagne P;Bray D;Murray BL;Hiebert B
2型糖尿病(T2D)在北美已经达到流行的程度。最近的证据表明，益生元可以调节肠道微生物群，从而在调节脂代谢、血糖和胰岛素敏感性方面发挥重要作用。因此，益生元正吸引着糖尿病前期和T2D的潜在治疗策略。本研究的主要目标是确定MSPreBiotic®抗消化淀粉(DRS)在健康中老年(ELD)成年人中的耐受性以及葡萄糖和胰岛素的调节能力。这是一项前瞻性、盲法、安慰剂对照研究。糖尿病前期和糖尿病是排除因素之一。招募了ELD(>；70 年)和MID(30-50 年)的加拿大成年人，在服用安慰剂2 周后，他们被随机分配为12 周，每天摄入30 g的MSPreBiotic®或安慰剂。总共有42名ELD和42名MID参与者完成了这项研究。在14周的研究中采集血样，并分析血糖、血脂、C反应蛋白、脂质颗粒、肿瘤坏死因子-α、白介素10、胰岛素和胰岛素抵抗(IR)。基线时，与中年人相比，特发性肝病患者中血糖升高和肿瘤坏死因子-α显著升高的百分比(p <； 0.01)显著升高(p <； 0.01)。MSPreBiotic®DRS在MID和ELD成人中都有良好的耐受性。与安慰剂相比，服用MSPreBiotic®的ELD成人随着时间的推移，血糖(p = 0.0301)和胰岛素水平(p = 0.009)以及IR(HOMA-IR；p = 0.009)有显著差异。在中年成年人中没有发现明显的变化。我们的结果表明，饮食中添加益生素，如MSPreBiotic®，可能是降低IR的有效策略的一部分，IR是在ELD中发生T2D的主要风险因素。在NIH网站上列出的NCT01977183，本研究中生成的元数据已提交给NCBI序列读取档案()。
Type 2 diabetes (T2D) has reached epidemic proportions in North America. Recent evidence suggests that prebiotics can modulate the gut microbiome, which then plays an important role in regulating lipid metabolism, blood glucose, and insulin sensitivity. As such, prebiotics are appealing potential therapeutic strategies for prediabetes and T2D. The key objectives of this study were to determine the tolerability as well as the glucose and insulin modulating ability of MSPrebiotic® digestion resistant starch (DRS) in healthy mid-age (MID) and elderly (ELD) adults. This was a prospective, blinded, placebo-controlled study. Prediabetes and diabetes were among the exclusion factors. ELD (>70 years) and MID (30–50 years) Canadian adults were recruited and, after 2 weeks of consuming placebo, they were randomized to consume 30 g of either MSPrebiotic® or placebo per day for 12 weeks. In total, 42 ELD and 42 MID participants completed the study. Blood samples were collected over the 14-week study and analyzed for glucose, lipid profile, and CRP, lipid particles, TNF-α, IL-10, insulin, and insulin resistance (IR). At baseline, the ELD population had a significantly higher percentage (p < 0.01) with elevated glucose and significantly higher TNF-α (p < 0.01) compared to MID adults. MSPrebiotic® DRS was well tolerated in both MID and ELD adults. There was a significant difference over time in blood glucose (p = 0.0301) and insulin levels (p = 0.009), as well as IR (HOMA-IR; p = 0.009) in ELD adults who consumed MSPrebiotic® compared to placebo. No significant changes were found in MID adults. Our results suggest that dietary supplementation with prebiotics such as MSPrebiotic® may be part of an effective strategy to reduce IR, a major risk factor for developing T2D, in the ELD. NCT01977183 listed on NIH website: , The metadata generated in this study have been submitted to the NCBI Sequence Read Archive ().